Abstract
Nitric oxide is a potent vasodilator that plays a critical role in disorders of erythrocyte function. Sickle cell disease, paroxysmal nocturnal hemoglobinuria and banked blood preservation are three conditions where nitric oxide is intimately related to dysfunctional erythrocytes. These conditions are accompanied by hemolysis, thrombosis and vasoocclusion. Our understanding of the interaction between nitric oxide, hemoglobin, and the vasculature is constantly evolving, and by defining this role we can better direct trials aimed at improving the treatments of disorders of erythrocyte function. Here we briefly discuss nitric oxide’s interaction with hemoglobin through the hypothesis regarding Snitrosohemoglobin, deoxyhemoglobin, and myoglobin as nitrite reductases. We then review the current understanding of the role of nitric oxide in sickle cell disease, paroxysmal nocturnal hemoglobinuria, and banked blood, and discuss therapeutics in development to target nitric oxide in the treatment of some of these disorders.
Keywords: Banked blood, erythrocytes, hemoglobin, nitric oxide, nitrite reductase, sickle cell disease.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Updated Role of Nitric Oxide in Disorders of Erythrocyte Function
Volume: 13 Issue: 1
Author(s): Marc J. Kahn, Jason H. Maley, George F. Lasker and Philip J. Kadowitz
Affiliation:
Keywords: Banked blood, erythrocytes, hemoglobin, nitric oxide, nitrite reductase, sickle cell disease.
Abstract: Nitric oxide is a potent vasodilator that plays a critical role in disorders of erythrocyte function. Sickle cell disease, paroxysmal nocturnal hemoglobinuria and banked blood preservation are three conditions where nitric oxide is intimately related to dysfunctional erythrocytes. These conditions are accompanied by hemolysis, thrombosis and vasoocclusion. Our understanding of the interaction between nitric oxide, hemoglobin, and the vasculature is constantly evolving, and by defining this role we can better direct trials aimed at improving the treatments of disorders of erythrocyte function. Here we briefly discuss nitric oxide’s interaction with hemoglobin through the hypothesis regarding Snitrosohemoglobin, deoxyhemoglobin, and myoglobin as nitrite reductases. We then review the current understanding of the role of nitric oxide in sickle cell disease, paroxysmal nocturnal hemoglobinuria, and banked blood, and discuss therapeutics in development to target nitric oxide in the treatment of some of these disorders.
Export Options
About this article
Cite this article as:
Kahn J. Marc, Maley H. Jason, Lasker F. George and Kadowitz J. Philip, Updated Role of Nitric Oxide in Disorders of Erythrocyte Function, Cardiovascular & Hematological Disorders-Drug Targets 2013; 13 (1) . https://dx.doi.org/10.2174/1871529X11313010009
DOI https://dx.doi.org/10.2174/1871529X11313010009 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CTO in Contemporary PCI
Current Cardiology Reviews Gene Therapy for Ischemic Brain Diseases
Current Gene Therapy An Overview of Bioactive Peptides for in vivo Imaging and Therapy in Human Diseases
Mini-Reviews in Medicinal Chemistry Drugs Interfering with Apoptosis in Breast Cancer
Current Pharmaceutical Design Editorial (Thematic Issue: Pharmacologic Strategies with Afterload Reduction in Low Cardiac Output Syndrome After Pediatric Cardiac Surgery)
Current Vascular Pharmacology Differential Action of Phytochemicals on Platelet Apoptosis: A Biological Overview
Current Medicinal Chemistry Dietary Antioxidants as Potential Pharmacological Agents for Ischemic Stroke
Current Medicinal Chemistry Melatonin in Cardiac Ischemia/Reperfusion-Induced Mitochondrial Adaptive Changes
Cardiovascular & Hematological Disorders-Drug Targets Therapeutic Neovascularization by the Implantation of Autologous Mononuclear Cells in Patients with Connective Tissue Diseases
Current Pharmaceutical Design Cardiac Biomarkers in Stroke, Alzheimer’s Disease, and Other Dementia. Are They of Use? A Brief Overview of Data from Recent Investigations
CNS & Neurological Disorders - Drug Targets Angiogenic Growth Factors in the Treatment of Peripheral Arterial Disease
Current Vascular Pharmacology Multifaceted Approach to Circadian Rhythm: Redox, Oxidative Stress, Melatonin, Antioxidants, Nitric Oxide, Hypoxia, Anesthetics, Cortisol and Cocaine
Current Chemical Biology Potential Non-neoplastic Applications for Polyphenols in Stem Cell Utilization
Current Drug Targets Cell-Based Therapy to Promote Angiogenesis in the Brain Following Ischemic Damage
Current Vascular Pharmacology Postoperative Atrial Fibrillation - What Do We Really Know?
Current Vascular Pharmacology Pharmacological, Immunological, and Gene Targeting of the Renin-Angiotensin System for Treatment of Cardiovascular Disease
Current Pharmaceutical Design Pathophysiology of Atherosclerotic Plaque Development
Cardiovascular & Hematological Agents in Medicinal Chemistry Flavonoids and Related Compounds in Non-Alcoholic Fatty Liver Disease Therapy
Current Medicinal Chemistry Connection between JAK/STAT and PPARγ Signaling During the Progression of Multiple Sclerosis: Insights into the Modulation of T-Cells and Immune Responses in the Brain
Current Molecular Pharmacology The Role of Endogenous H2S in Cardiovascular Physiology
Current Pharmaceutical Biotechnology